[Using doxasosine and finasteride combination in the treatment of prostate adenoma].
The study was made in 2005-2006 of efficacy and safety of combined use of doxasosine and finasteride in patients (n = 50, age 53-83) with symptoms of lower urinary tract dysfunction (LUTD) caused by prostatic adenoma. LUTD severity by IPSS, size of the prostate, maximal and mean urinary flow velocity, functional capacity of the urinary bladder, residual urine, blood pressure, a PSA level, sexual function, were assessed at baseline and after the treatment. Side effects were also registered. Combined treatment with doxasosine plus finasteride significantly lowered both obstructive and irritative LUTD symptoms by IPSS, quality of life improved from 3.4 to 2.3 scores (p < 0.01), maximal urinary flow and mean urinary flow velocity increased from 10.2 to 11.6 ml/s and from 5.4 to 6.1 ml/s, respectively, residual urine reduced from 35.2 to 7.7 ml (p < 0.01). The size of the prostate diminished from 55.8 to 46 cm(3) (p < 0.01). PSA decreased from 2.8 to 1.4 ng/ml. Erectile function did not worsen. Thus, the proposed scheme of combined treatment improves quality of life, voiding; lowers residual urine; is well tolerated; can be recommended as a basic scheme of treatment in patients with a risk of prostatic adenoma progression.
Bogdanov
A B
AB
Luk'ianov
I V
IV
Veliev
E I
EI
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D017292:Doxazosin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018120:Finasteride / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D012735:Sexual Dysfunction, Physiological / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects*
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D018120:Finasteride; D017292:Doxazosin